Senti Biosciences, Inc.
General ticker "SNTI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $13.5M (TTM average)
Senti Biosciences, Inc. does not follow the US Stock Market performance with the rate: -29.2%.
Estimated limits based on current volatility of 2.0%: low 1.03$, high 1.10$
Factors to consider:
- Total employees count: 122 (+2950.0%) as of 2022
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: High R&D costs, Market volatility, Regulatory and compliance, Operational and conduct risks, Supply chain disruptions
- Current price 44.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.48$, 7.88$]
- 2025-12-31 to 2026-12-31 estimated range: [1.85$, 6.01$]
Financial Metrics affecting the SNTI estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -229.90 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: 19.35 < Shareholder equity ratio, % of 26.21 <= 42.53
- Negative: negative Net income
- Negative: -0.18 < Industry inventory ratio change (median), % of 0
- Negative: Industry earnings per price (median), % of -16.21 <= 0
Short-term SNTI quotes
Long-term SNTI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.29MM | $1.98MM | $0.00MM |
| Operating Expenses | $65.37MM | $94.70MM | $61.04MM |
| Operating Income | $-62.08MM | $-92.73MM | $-61.04MM |
| Non-Operating Income | $12.42MM | $9.32MM | $8.25MM |
| R&D Expense | $28.14MM | $32.15MM | $34.36MM |
| Income(Loss) | $-49.66MM | $-83.41MM | $-52.79MM |
| Other Income(Loss) | $-8.54MM | $12.35MM | $0.00MM |
| Profit(Loss)* | $-58.21MM | $-58.71MM | $-52.79MM |
| Stockholders Equity | $127.26MM | $66.91MM | $25.65MM |
| Assets | $180.79MM | $119.48MM | $97.84MM |
| Operating Cash Flow | $-34.90MM | $-52.40MM | $-41.40MM |
| Capital expenditure | $41.37MM | $12.04MM | $0.03MM |
| Investing Cash Flow | $-81.96MM | $30.08MM | $0.03MM |
| Financing Cash Flow | $118.55MM | $0.78MM | $53.73MM |
| Earnings Per Share** | $-13.25 | $-13.23 | $-11.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.